The Effect of Cilostazol on Right Heart Function and Pulmonary Pressure
| Autor: | Taylan Akgun, Mehmet Muhsin Turkmen, Serdar Demir, Muslum Sahin, Gökhan Alıcı, Elnur Alizade, Selçuk Pala, Mehmet Vefik Yazıcıoğlu, Yunus Emiroglu, Birol Özkan |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Ventricular Ejection Fraction Hypertension Pulmonary Phosphodiesterase 3 Tetrazoles Pulmonary Artery Phosphodiesterase 3 Inhibitors Doppler imaging Oral administration medicine.artery Internal medicine medicine Humans Familial Primary Pulmonary Hypertension Pharmacology (medical) Isovolumetric contraction Aged Pharmacology business.industry General Medicine Middle Aged Cilostazol Peripheral Anesthesia Pulmonary artery Ventricular Function Right Cardiology Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular Therapeutics. 31:e88-e93 |
| ISSN: | 1755-5914 |
| Popis: | Summary Introduction Cilostazol is a PDE3 inhibitor and used to treat peripheral arterial disease. There are few reports on the influence of cilostazol on heart. Aims The aim of this study was to assess this effect on right ventricular function and pulmonary artery pressure. Methods Forty patients with normal left and right ventricular ejection fraction and mild or moderate pulmonary artery hypertension were enrolled in the study. Right ventricular function was assessed by tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), tissue Doppler imaging (TDI), and two-dimensional speckle-tracking echocardiography (2D-STE) before and after oral administration of cilostazol. Also pulmonary artery pressure assessed before and after administration of cilostazol. Results After cilostazol administration, there were significant increases in the TAPSE (1.9 ± 0.3 cm vs. 2.2 ± 0.3 cm, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |